TW200908976A - Cancer treatment combination therapy comprising vinflunine and trastuzumab - Google Patents

Cancer treatment combination therapy comprising vinflunine and trastuzumab Download PDF

Info

Publication number
TW200908976A
TW200908976A TW097117418A TW97117418A TW200908976A TW 200908976 A TW200908976 A TW 200908976A TW 097117418 A TW097117418 A TW 097117418A TW 97117418 A TW97117418 A TW 97117418A TW 200908976 A TW200908976 A TW 200908976A
Authority
TW
Taiwan
Prior art keywords
treatment
tumor
trastuzumab
vinflunine
cancer
Prior art date
Application number
TW097117418A
Other languages
English (en)
Chinese (zh)
Inventor
Bart Vanhauwere
Marie-Claire Pinel
Francois-Michel Delgado
Original Assignee
Pf Medicament
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38353425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200908976(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament, Hoffmann La Roche filed Critical Pf Medicament
Publication of TW200908976A publication Critical patent/TW200908976A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW097117418A 2007-05-31 2008-05-12 Cancer treatment combination therapy comprising vinflunine and trastuzumab TW200908976A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07290679A EP1997534A1 (en) 2007-05-31 2007-05-31 Cancer treatment combination therapy comprising vinflunine and trastuzumab

Publications (1)

Publication Number Publication Date
TW200908976A true TW200908976A (en) 2009-03-01

Family

ID=38353425

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097117418A TW200908976A (en) 2007-05-31 2008-05-12 Cancer treatment combination therapy comprising vinflunine and trastuzumab

Country Status (18)

Country Link
US (1) US20100196363A1 (enExample)
EP (2) EP1997534A1 (enExample)
JP (1) JP2010528091A (enExample)
KR (1) KR20100017752A (enExample)
CN (1) CN101687104A (enExample)
AR (1) AR066778A1 (enExample)
AU (1) AU2008257555A1 (enExample)
BR (1) BRPI0812280A2 (enExample)
CA (1) CA2689664A1 (enExample)
CL (1) CL2008001589A1 (enExample)
IL (1) IL202393A0 (enExample)
MX (1) MX2009012874A (enExample)
NO (1) NO20093536L (enExample)
RU (1) RU2009146882A (enExample)
TN (1) TN2009000490A1 (enExample)
TW (1) TW200908976A (enExample)
WO (1) WO2008145697A1 (enExample)
ZA (1) ZA200908247B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MY194408A (en) 2011-10-14 2022-11-30 Genentech Inc Uses for and Article of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab
TWI554284B (zh) 2013-04-16 2016-10-21 建南德克公司 帕妥珠單抗（ｐｅｒｔｕｚｕｍａｂ）變體及其評估
US20190307741A1 (en) * 2016-07-06 2019-10-10 Pierre Fabre Medicament Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination
CN117752782A (zh) 2017-01-17 2024-03-26 豪夫迈·罗氏有限公司 皮下her2抗体配制剂
CN116531511A (zh) 2017-03-02 2023-08-04 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
KR20250151568A (ko) 2020-06-29 2025-10-21 제넨테크, 인크. 퍼투주맙 + 트라스투주맙 고정 용량 조합

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707988B1 (fr) * 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation

Also Published As

Publication number Publication date
BRPI0812280A2 (pt) 2014-11-18
EP1997534A1 (en) 2008-12-03
TN2009000490A1 (en) 2011-03-31
ZA200908247B (en) 2010-10-27
EP2164573A1 (en) 2010-03-24
AU2008257555A1 (en) 2008-12-04
MX2009012874A (es) 2010-03-31
IL202393A0 (en) 2010-06-30
KR20100017752A (ko) 2010-02-16
NO20093536L (no) 2009-12-16
WO2008145697A1 (en) 2008-12-04
US20100196363A1 (en) 2010-08-05
CA2689664A1 (en) 2008-12-04
CL2008001589A1 (es) 2009-03-06
RU2009146882A (ru) 2011-07-10
JP2010528091A (ja) 2010-08-19
CN101687104A (zh) 2010-03-31
AR066778A1 (es) 2009-09-09

Similar Documents

Publication Publication Date Title
TW200908976A (en) Cancer treatment combination therapy comprising vinflunine and trastuzumab
Taylor et al. Glioblastoma multiforme: an overview of emerging therapeutic targets
Dunn et al. A phase 1b study of cetuximab and BYL719 (Alpelisib) concurrent with intensity modulated radiation therapy in stage III-IVB head and neck squamous cell carcinoma
Pan et al. β-glucan-coupled superparamagnetic iron oxide nanoparticles induce trained immunity to protect mice against sepsis
Kudoh et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.
JP2023539715A (ja) 抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ
CA2752890C (en) Method for preventing and treating hyperpermeability
CN109310754A (zh) 使用包含抗erbb3抗体的联合疗法治疗er+、her2-、hrg+乳腺癌的方法
Dunn et al. Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus‐associated oropharyngeal squamous cell cancer
Moser et al. Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer
Ramezani et al. The role of kinase signaling in resistance to bevacizumab therapy for glioblastoma multiforme
TW201127374A (en) Novel antitumoral use of cabazitaxel
CN104997808A (zh) 用于治疗癌症的方法和组合物
WO2015172712A1 (zh) 维生素c与抗肿瘤药物协同作用的注射用药物组合物
Gelmon et al. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
CN106924260B (zh) 化合物在制备用于治疗脑胶质瘤的药物中的用途
Xu et al. A fixed human umbilical vein endothelial cell vaccine with 2 tandem repeats of microbial HSP70 peptide epitope 407-426 as adjuvant for therapy of hepatoma in mice
EP2999465A1 (en) Specific cancer treatment regimens with ganetespib
JP2008501006A (ja) Ｓｒｃキナーゼ阻害剤ＡＺＤ０５３０、および、抗エストロゲン剤またはＥＧＦＲ−ＴＫ−阻害剤を含む組み合わせ製品
US20220370496A1 (en) Her3 pulsed dc1 therapy
WO2025103379A1 (zh) 抗b7h3抗体-药物偶联物治疗癌症的方法
Hong et al. Preoperative chemoradiotherapy in the management of localized rectal cancer: the new standard
EP4659741A1 (en) Use of paclitaxel cationic liposome in treating tumors
US20250049802A1 (en) Combination therapies and uses for treating cancer
Zhen et al. The sequence of drug administration influences the antitumor effects of bevacizumab and cyclophosphamide in a neuroblastoma model